Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2391-2400

  Sandberg, Anne ^a   Jensen, Klaus Skovbo ^a   Baudoux, Pierre ^b   Van Bambeke, Françoise ^b   Tulkens, Paul M ^b   Frimodt Møller, Niels ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOXACILLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG HALF LIFE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STEADY STATE;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; COLONY COUNT, MICROBIAL; DICLOXACILLIN; EXTRACELLULAR SPACE; FEMALE; HUMANS; INTRACELLULAR SPACE; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; PERITONITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 77952635259     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01400-09     Document Type: Article

References (46)

1. Andes, D., and W. A. Craig. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268.
2. Bamberger, D. M., and S. E. Boyd. 2005. Management of Staphylococcus aureus infections. Am. Fam. Physician 72:2474-2481.
3. Barcia-Macay, M., C. Seral, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50:841-851.
4. Baudoux, P., N. Bles, S. Lemaire, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2007. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J. Antimicrob. Chemother. 59:246-253.
5. Brouillette, E., G. Grondin, L. Shkreta, P. Lacasse, and B. G. Talbot. 2003. In vivo and in vitro demonstration that Staphylococcus aureus is an intracellular pathogen in the presence or absence of fibronectin-binding proteins. Microb. Pathog. 35:159-168.
6. Carryn, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2002. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob. Agents Chemother. 46:2095-2103.
7. Carryn, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2003. Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. J. Antimicrob. Chemother. 51:1051-1052.
8. Chang, F. Y., J. E. Peacock, Jr., D. M. Musher, P. Triplett, B. B. MacDonald, J. M. Mylotte, A. O'Donnell, M. M. Wagener, and V. L. Yu. 2003. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82:333-339.
9. Ciampolini, J., and K. G. Harding. 2000. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad. Med. J. 76: 479-483.
10. Clement, S., P. Vaudaux, P. Francois, J. Schrenzel, E. Huggler, S. Kampf, C. Chaponnier, D. Lew, and J. S. Lacroix. 2005. Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J. Infect. Dis. 192:1023-1028.
11. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 15th informational supplement (M100-S15). Clinical and Laboratory Standards Institute, Wayne, PA.
12. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17:479-501.
13. Ellington, J. K., M. Harris, L. Webb, B. Smith, T. Smith, K. Tan, and M. Hudson. 2003. Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. J. Bone Joint Surg. Br. 85:918-921.
14. Elliott, G. R., P. K. Peterson, H. A. Verbrugh, M. R. Freiberg, J. R. Hoidal, and P. G. Quie. 1982. Influence of subinhibitory concentrations of penicillin, cephalothin, and clindamycin on Staphylococcus aureus growth in human phagocytic cells. Antimicrob. Agents Chemother. 22:781-784.
15. Ferrara, A. M. 2007. Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 30: 19-24.
16. Fowler, V. G., Jr., J. M. Miro, B. Hoen, C. H. Cabell, E. Abrutyn, E. Rubinstein, G. R. Corey, D. Spelman, S. F. Bradley, B. Barsic, P. A. Pappas, K. J. Anstrom, D. Wray, C. Q. Fortes, I. Anguera, E. Athan, P. Jones, J. T. van der Meer, T. S. Elliott, D. P. Levine, and A. S. Bayer. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293: 3012-3021.
17. Frimodt-Moller, N. 1988. Correlation of in vitro activity and pharmacokinetic parameters with effect in vivo for antibiotics. Observations from experimental pneumococcus infection. Dan. Med. Bull. 35:422-437.
18. Frimodt-Moller, N. 1993. The mouse peritonitis model: present and future use. J. Antimicrob. Chemother. 31(Suppl. D):55-60.
19. Frimodt-Moller, N., V. T. Rosdahl, G. Sorensen, S. H. Hartzen, and M. W. Bentzon. 1986. Relationship between penicillinase production and the invitro activity of methicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, and cephalothin against strains of Staphylococcus aureus of different phage patterns and penicillinase activity. J. Antimicrob. Chemother. 18:27-33.
20. Grayson, M. L. 2006. The treatment triangle for staphylococcal infections. N. Engl. J. Med. 355:724-727.
21. Gresham, H. D., J. H. Lowrance, T. E. Caver, B. S. Wilson, A. L. Cheung, and F. P. Lindberg. 2000. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J. Immunol. 164:3713-3722.
22. Hess, D. J., M. J. Henry-Stanley, E. A. Erickson, and C. L. Wells. 2003. Intracellular survival of Staphylococcus aureus within cultured enterocytes. J. Surg. Res. 114:42-49.
23. Hughes, D. W., C. R. Frei, P. R. Maxwell, K. Green, J. E. Patterson, G. E. Crawford, and J. S. Lewis. 2009. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin- susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2014-2019.
24. Iyer, S., and D. H. Jones. 2004. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J. Am. Acad. Dermatol. 50:854-858.
25. Jensen, A. G., F. Espersen, P. Skinhoj, and N. Frimodt-Moller. 1998. Bacteremic Staphylococcus aureus spondylitis. Arch. Intern. Med. 158:509-517.
26. Jensen, A. G., C. H. Wachmann, F. Espersen, J. Scheibel, P. Skinhoj, and N. Frimodt-Moller. 2002. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch. Intern. Med. 162:25-32.
27. Johnson, L. B., M. O. Almoujahed, K. Ilg, L. Maolood, and R. Khatib. 2003. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand. J. Infect. Dis. 35:782-789.
28. Kuehnert, M. J., H. A. Hill, B. A. Kupronis, J. I. Tokars, S. L. Solomon, and D. B. Jernigan. 2005. Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerg. Infect. Dis. 11:868-872.
29. Lemaire, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2005. Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J. Antimicrob. Chemother. 55:897-904.
30. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
31. Lowy, F. D. 2000. Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol. 8:341-343.
32. Mempel, M., C. Schnopp, M. Hojka, H. Fesq, S. Weidinger, M. Schaller, H. C. Korting, J. Ring, and D. Abeck. 2002. Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br. J. Dermatol. 146:943-951.
33. Nguyen, H. A., O. Denis, A. Vergison, P. M. Tulkens, M. J. Struelens, and F. Van Bambeke. 2009. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations. Antimicrob. Agents Chemother. 53:1443-1449.
34. Pedersen, M., T. L. Benfield, P. Skinhoej, and A. G. Jensen. 2006. Haematogenous Staphylococcus aureus meningitis. A 10-year nationwide study of 96 consecutive cases. BMC Infect. Dis. 6:49.
35. Qazi, S. N., E. Counil, J. Morrissey, C. E. Rees, A. Cockayne, K. Winzer, W. C. Chan, P. Williams, and P. J. Hill. 2001. agr expression precedes escape of internalized Staphylococcus aureus from the host endosome. Infect. Immun. 69:7074-7082.
36. Risson, D. C., E. D. O'Connor, R. W. Guard, J. M. Schooneveldt, and G. R. Nimmo. 2007. A fatal case of necrotising pneumonia due to community-associated methicillin-resistant Staphylococcus aureus. Med. J. Aust. 186: 479-480.
37. Roder, B. L., D. A. Wandall, N. Frimodt-Moller, F. Espersen, P. Skinhoj, and V. T. Rosdahl. 1999. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch. Intern. Med. 159:462-469.
38. Sanabria, T. J., J. S. Alpert, R. Goldberg, L. A. Pape, and S. H. Cheeseman. 1990. Increasing frequency of staphylococcal infective endocarditis. Experience at a university hospital, 1981 through 1988. Arch. Intern. Med. 150: 1305-1309.
39. Sandberg, A., J. H. Hessler, R. L. Skov, J. Blom, and N. Frimodt-Moller. 2009. Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. Antimicrob. Agents Chemother. 53:1874-1883.
40. Scorneaux, B., Y. Ouadrhiri, G. Anzalone, and P. M. Tulkens. 1996. Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. Antimicrob. Agents Chemother. 40:1225-1230.
41. Seral, C., F. Van Bambeke, and P. M. Tulkens. 2003. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob. Agents Chemother. 47:2283-2292.
42. Tulkens, P. M. 1991. Intracellular distribution and activity of antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 10:100-106.
43. Tuomanen, E., R. Cozens, W. Tosch, O. Zak, and A. Tomasz. 1986. The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J. Gen. Microbiol. 132:1297-1304.
44. Van Bambeke, F., M. Barcia-Macay, S. Lemaire, and P. M. Tulkens. 2006. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Dev. 9:218-230.
45. Van Bambeke, F., S. Carryn, C. Seral, H. Chanteux, D. Tyteca, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2004. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. 48: 2853-2860.
46. Watanakunakorn, C. 1994. Staphylococcus aureus endocarditis at a community teaching hospital, 1980 to 1991. An analysis of 106 cases. Arch. Intern. Med. 154:2330-2335.